Community hub
Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 1 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
2C-T-13 AI simulator
(@2C-T-13_simulator)
Hub AI
2C-T-13 AI simulator
(@2C-T-13_simulator)
2C-T-13
2C-T-13, also known as 4-(2-methoxyethylthio)-2,5-dimethoxyphenethylamine, is a psychedelic phenethylamine of the 2C family. It was presumably first synthesized by Alexander Shulgin and reported in his book PiHKAL.
The dose range of 2C-T-13 is 25 to 40 mg and its duration is approximately 6 to 8 hours according to Alexander Shulgin. 2C-T-13 produces many closed-eye visuals and geometric patterns. It also produces slight visual distortion.
The drug has structural properties similar to mescaline and other drugs in the 2C-T series, with the most closely related compounds being 2C-T-7 and 2C-T-21.
2C-T-13 was first described in the scientific literature by Alexander Shulgin and colleagues in 1991. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
As of October 31, 2016, 2C-T-13 is a controlled substance (Schedule III) in Canada.
2C-T-13 is not scheduled in the United States, but possession and sales of 2C-T-13 could be prosecuted under the Federal Analog Act because of its structural similarities to 2C-T-7.
2C-T-13
2C-T-13, also known as 4-(2-methoxyethylthio)-2,5-dimethoxyphenethylamine, is a psychedelic phenethylamine of the 2C family. It was presumably first synthesized by Alexander Shulgin and reported in his book PiHKAL.
The dose range of 2C-T-13 is 25 to 40 mg and its duration is approximately 6 to 8 hours according to Alexander Shulgin. 2C-T-13 produces many closed-eye visuals and geometric patterns. It also produces slight visual distortion.
The drug has structural properties similar to mescaline and other drugs in the 2C-T series, with the most closely related compounds being 2C-T-7 and 2C-T-21.
2C-T-13 was first described in the scientific literature by Alexander Shulgin and colleagues in 1991. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
As of October 31, 2016, 2C-T-13 is a controlled substance (Schedule III) in Canada.
2C-T-13 is not scheduled in the United States, but possession and sales of 2C-T-13 could be prosecuted under the Federal Analog Act because of its structural similarities to 2C-T-7.
Recent media
Recent media